CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adu-Gyamfi, Y.
Right arrow Articles by Marwa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adu-Gyamfi, Y.
Right arrow Articles by Marwa, S.

Canadian Journal of Anesthesia, Vol 40, 24-27, Copyright © 1993 by Canadian Anesthesiologists' Society

ARTICLES

Use of a tourniquet in patients with sickle-cell disease

Y Adu-Gyamfi, M Sankarankutty and S Marwa
Department of Anaesthesiology, King Faisal University, College of Medicine, Dammam, Saudi Arabia.

Fifteen patients, 13 male and two female, known to be carrying the sickle-cell gene (12 HbSS and 3 HbAS), who were undergoing operations requiring a bloodless field, were included in the study. Of the 12 with HbSS, seven had haemoglobin A1 component of between 11 and 27%, three had fetal haemoglobin ranging from 5.7 to 29% and the remaining two had increased haemoglobin A2 concentrations suggesting a beta non-thalassaemia combination. All had a tourniquet applied to the appropriate limb and were given general anaesthesia with moderate hyperventilation throughout the procedure. The tourniquet inflation time was 61.7 +/- 27.5 min. The mean PaO2 remained above 200 mmHg, mean PaCO2 was less than 37 mmHg, and pH ranged between 7.40 and 7.45. There were no clinically important changes in BP or ECG. All patients made uneventful recoveries and none developed sickle-cell crises. It is suggested that it is safe to use tourniquet in patients with sickle-cell disease provided optimum acid-base status and oxygenation are maintained throughout the procedure.


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
P. G. Firth
Anaesthesia for peculiar cells--a century of sickle cell disease
Br. J. Anaesth., September 1, 2005; 95(3): 287 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. M. Sarjeant, J. L. Callum, and A. A. Al-Ghamdi
The Use of Tourniquets in Patients with Sickle Cell Disease * Response
Anesth. Analg., August 1, 2004; 99(2): 630 - 630.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. R. Tobin and J. Butterworth
Sickle Cell Disease: Dogma, Science, and Clinical Care
Anesth. Analg., February 1, 2004; 98(2): 283 - 284.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. Abdulla Al-Ghamdi
Bilateral Total Knee Replacement with Tourniquets in a Homozygous Sickle Cell Patient
Anesth. Analg., February 1, 2004; 98(2): 543 - 544.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
A. Wakai, D. C. Winter, J. T. Street, and P. H. Redmond
Pneumatic Tourniquets in Extremity Surgery
J. Am. Acad. Ortho. Surg., September 1, 2001; 9(5): 345 - 351.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the Canadian Anesthesiologists' Society.